Survey Reveals that Serialization Investments to Meet DSCSA Mandates are Expected to Deliver Business Value beyond Compliance
March 4, 2016
Improved returns and recall management are imperative goals cited by 42% of respondents
Marlton, NJ – February 8, 2016 – According to a 2016 survey conducted by Acsis and Pharmaceutical Commerce, manufacturers taking a “compliance now” approach to serialization will likely get caught with longer-term costs and rework to build a truly traceable, serialized warehouse. See the detailed results here.
Acsis, a leading provider of supply chain serialization solutions, undertook the survey to uncover expectations for payback from companies’ compliance costs. The survey results will be addressed in a free Pharmaceutical Commerce webinar, beginning February 10 at 2 p.m. EST (register here).
The Drug Supply Chain Security Act (DSCSA) dictates that manufacturers serialize each product (or saleable unit) and electronically share that serialization data with supply partners by November 2017. This deadline is just one of many leading to the ultimate DSCSA mandate of complete unit-level traceability with aggregation and inference, which for most companies will require major technology investments, as well as drastic changes to supply chain processes and warehouse workflows.
While many manufacturers are on their way to deploying serialization at the packaging line, 43% are concerned about the warehouse serialization challenges of technical integration and 53% about the readiness of their outsourced partners.
Supply chain managers expect that the enhanced precision and extended visibility from the serialization investment will deliver value-based and revenue-generating payback, such as more precise chargebacks and less grey market leakage. Forty-two percent of respondents expect to improve both returns and recall management and 32% cite brand protection as a key anticipated benefit.
“While immediate compliance may be the initial driver for serialization, it’s clear that it shouldn’t be the only driving force behind a solution choice and deployment. Without a longer-term view of compliance mandates and milestones, companies run the risk of adding even more disintegrated systems, additional manual processes and rework of current initiatives.”
– John DiPalo, Chief Strategy Officer at Acsis, Inc.
Acsis Edge serialization solutions not only address DSCSA compliance mandates, but also deliver better operational traceability and seamless integration with ERP, EPICS and warehouse management systems. With streamlined serialization, data collection and management from the production line through the entire supply network, companies gain a foundation for tighter returns and recall processes.
About Pharmaceutical Commerce
Pharmaceutical Commerce (www.PharmaceuticalCommerce.com), a leading industry publication serving pharma manufacturers and their trading partners, focuses on all issues pertaining to pharmaceutical commercialization: product flows, information flows and business services for launching products and maintaining markets. It has been covering the serialization/traceability issue since the early 2000s.
For over 20 years, Acsis has provided warehouse execution systems for Fortune 500 pharmaceutical companies. With our Acsis Edge solution, companies ensure compliance with the Drug Supply Chain Security Act and other serialization mandates, while leveraging their serialization data to increase productivity, improve order accuracy, and build a foundation for returns, chargebacks and recall management.
Acsis is headquartered in Marlton, NJ. Customers include AbbVie, Amerisource Bergen, Ashland, Cintas, DuPont, Glatfelter, Hershey’s, Meda and OSRAM. www.acsisinc.com
Acsis and Acsis Edge are trademarks or registered trademarks of Acsis Inc. Other company names, product names and company logos mentioned herein are the trademarks, or registered trademarks of their respective owners.